Allergic reactions to oxaliplatin in a single institute in Japan.
Allergic reactions to oxaliplatin can be severe and are an important cause of discontinuation of treatment. A retrospective review was performed for 105 patients who received FOLFOX regimens between May 2005 and June 2007. Twenty-five cases (23.8%) of allergic reactions were identified, including 9 late onset reactions (8.6%) and 16 immediate reactions (15.2%). Severe allergy (Grades 3 and 4) occurred in seven patients (6.7%). Re-introduction of FOLFOX was attempted for seven immediate onset patients with a severity grade of 1 or 2, and three of these patients (42.9%) showed relapse of allergy. In approximately 10% of the patients, FOLFOX had to be discontinued due to allergy before the disease became refractory to the regimen. Our experience indicates that allergy to oxaliplatin may be a significant concern and that methods are required for suppression of this allergy.
Ichikawa
Yasushi
Y
Department of Clinical Oncology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. yasu0514@med.yokohama-cu.ac.jp.
Goto
Ayumu
A
Hirokawa
Satoru
S
Kijima
Miyuki
M
Ishikawa
Takashi
T
Chishima
Takashi
T
Suwa
Hirokazu
H
Yamamoto
Harumi
H
Yamagishi
Shigeru
S
Osada
Shunichi
S
Ota
Mitsuyoshi
M
Fujii
Shoichi
S
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D004342:Drug Hypersensitivity / Q000209:etiology*; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects; D006801:Humans; D007564:Japan; D002955:Leucovorin / Q000009:adverse effects; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D000077150:Oxaliplatin; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate
D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil